- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06889727
Pregnancy and Childbirth in Women with Thalassemia Yesterday and Today
March 17, 2025 updated by: Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia
Pregnancy and Childbirth in Women with Thalassemia Yesterday and Today: a Multicentre Observational Study
Recent advances in the management of thalassemia have significantly improved life expectancy and quality of life of patients with this hemoglobinopathy, with a consequent increase in their reproductive potential and desire to have children.Since an initial report of a successful pregnancy in a woman with thalassemia major by Walker in 1969, hundreds of pregnancies have been reported so far, highlighting that women carefully managed in the preconception phase usually carry out a successful gestation and labor, both in case of spontaneous conception and assisted reproductive techniques.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
75
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cagliari, Italy, 09123
- UniversityCagliari, OspPed Microcitemico, Cagliari
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
FEMALE THALASSEMIE DEPEND TRANSFUSION
Description
Inclusion Criteria:
- Transfusion dependent and nontransfusion- dependent thalassemia
- Pregnancy ended with the birth of a live or dead foetus
- Pregnancy ended in miscarriage or voluntary abortion
- Pregnancy in progress
Exclusion Criteria:
- Other types of anemia
- Pregnancy not initiated despite assisted fertilization practices
- Subjects unwilling to sign informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of pregnancies in women with beta thalassemia followed in Italian centres
Time Frame: 15 YEARS
|
To evaluate the number of pregnancies in women with beta thalassemia followed in Italian centres and how the increase in the average age of the thalassemia population impact on the number of new pregnancies over time
|
15 YEARS
|
|
number of pregnancies spontaneously
Time Frame: 15 YEARS
|
many pregnancies occurred spontaneously
|
15 YEARS
|
|
number of pregnancies after hormonal stimulation
Time Frame: 15 YEARS
|
number of pregnancies after hormonal stimulation
|
15 YEARS
|
|
likelihood of miscarriage
Time Frame: 15 YEARS
|
To evaluate the likelihood of miscarriage
|
15 YEARS
|
|
foetal death
Time Frame: 15 YEARS
|
To evaluate foetal death
|
15 YEARS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 9, 2023
Primary Completion (Actual)
May 14, 2024
Study Completion (Actual)
May 14, 2024
Study Registration Dates
First Submitted
March 17, 2025
First Submitted That Met QC Criteria
March 17, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
March 17, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRAV001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thalassemia
-
University of California, San FranciscoRecruitingAlpha-Thalassemia | Alpha Thalassemia Major | Alpha Thalassemia MinorUnited States
-
Guangzhou Women and Children's Medical CenterRecruitingThalassemia Majors (Beta-Thalassemia Major) | Haplo-identical DonorsChina
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Denmark, Thailand, Malaysia, United States, Netherlands, Italy, Canada, Greece, Brazil, France, United Kingdom, United Arab Emirates, Bulgaria, Saudi Arabia, Taiwan, Turkey (Türkiye), Lebanon
-
Editas Medicine, Inc.Active, not recruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
Agios Pharmaceuticals, Inc.Active, not recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Italy, Bulgaria, United Kingdom, Greece, United Arab Emirates, Brazil, Denmark, Saudi Arabia, Lebanon, Turkey (Türkiye)
-
Shiraz University of Medical SciencesCompletedCombination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaIran, Islamic Republic of
-
Assiut UniversityNot yet recruitingThalassemia Majors (Beta-Thalassemia Major)
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
Agios Pharmaceuticals, Inc.Not yet recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-Thalassemia
-
Ataturk UniversityNot yet recruitingBeta Thalassemia Major | Thalassemia Majors (Beta-Thalassemia Major)Turkey